High Tide Resources Announces Non-Brokered Private Placement GlobeNewswire August 06, 2025 NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR RELEASE, PUBLICATION, DISTRIBUTION OR DISSEMINATION DIRECTLY, OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES TORONTO, Aug. 06, 2025 (GLOBE NEWSWIRE) — High Tide Resources Corp. (“High Tide Resources” or the […]

OTC Markets Group Welcomes Alkane Resources Limited to OTCQX GlobeNewswire August 06, 2025 NEW YORK, Aug. 06, 2025 (GLOBE NEWSWIRE) — OTC Markets Group Inc. (OTCQX: OTCM), operator of regulated markets for trading 12,000 U.S. and international securities, today announced Alkane Resources Limited (ASX: ALK; OTCQX: ALKEF), a diversified Australia-based gold and antimony producer, has

Upstream Bio Reports Second Quarter 2025 Financial Results and Highlights Continued Progress GlobeNewswire August 06, 2025 – On track to report top-line data from Phase 2 trial in chronic rhinosinusitis with nasal polyps (CRSwNP) in the third quarter of 2025 – – Completed enrollment in Phase 2 trial in severe asthma in June 2025; top-line

Trident Resources to Commence Inaugural 5,000m Drill Program at Contact Lake High-Grade Gold Project, Saskatchewan GlobeNewswire August 06, 2025 Vancouver, BC, Aug. 06, 2025 (GLOBE NEWSWIRE) — Trident Resources Corp. (TSX-V: ROCK) (OTCQB: TRDTF) (“Trident” or the “Company“) is pleased to announce an upcoming fully-funded 5,000-metre drill program at its high-grade Contact Lake Gold Project,

Arvinas Reports Second Quarter 2025 Financial Results and Provides Corporate Update GlobeNewswire August 06, 2025 – Submitted New Drug Application for vepdegestrant for the treatment of ESR1m, ER+/HER2- advanced or metastatic breast cancer – – Presented ARV-102 SAD and MAD data from the Phase 1 clinical trial in healthy volunteers; initiated dosing in patients with

Bioventus Reports Second Quarter Financial Results GlobeNewswire August 06, 2025 Q2 reported revenue of $147.7 million declined 2.4%; Organic* revenue advanced 6.2% Second quarter diluted earnings per share was $0.11 compared to a diluted loss per share of $0.40 in the prior-year period Non-GAAP earnings* of $0.21 per share increased 31% Cash from operations of

Seres Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Updates GlobeNewswire August 06, 2025 Following FDA input, Seres submitted Phase 2 study protocol to FDA for SER-155 for the prevention of bloodstream infections (BSIs) in adults undergoing allogeneic hematopoietic stem cell transplant (allo-HSCT) to treat hematological malignancies Seres engaging with multiple parties regarding

Harrow to Present at H.C. Wainwright 5th Annual Ophthalmology Conference GlobeNewswire August 06, 2025 NASHVILLE, Tenn., Aug. 06, 2025 (GLOBE NEWSWIRE) — Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, today announced that management will participate in H.C. Wainwright's 5th Annual Ophthalmology Conference on Wednesday, August 13, 2025, being held virtually. Harrow's Chief

Telesat Reports Results for the Quarter and Six Months Ended June 30, 2025 GlobeNewswire August 06, 2025 OTTAWA, Ontario, Aug. 06, 2025 (GLOBE NEWSWIRE) — Telesat (Nasdaq and TSX: TSAT), one of the world's largest and most innovative satellite operators, today announced its financial results for the three and six-month periods ended June 30, 2025.

Verrica Pharmaceuticals to Report Second Quarter 2025 Financial Results and Provide a Corporate Update on August 12, 2025 GlobeNewswire August 06, 2025 WEST CHESTER, Pa., Aug. 06, 2025 (GLOBE NEWSWIRE) — Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that